Medico Remedies profit and loss

Latest FY26
Revenue
₹206cr+36.7% on FY25
EBITDA
₹17.0cr+13.5% on FY25
Net profit
₹13.1cr+29.9% on FY25
EPS
₹1.58+29.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
238206151145140
6.45.92.72.13.9
244212154147144
Expenses
167149111106100
5.04.42.11.86.0
7.7−1.7−5.22.0−1.2
7.77.46.35.95.7
1.91.81.20.80.7
3.03.13.02.92.7
32.630.621.316.220.3
225194140136134
17.517.015.012.99.6
14.513.912.010.06.9
Profit
19.018.113.511.310.1
19.018.113.511.310.1
5.25.13.83.22.5
−0.1−0.1−0.4−0.10.4
5.24.93.43.02.9
13.813.110.18.37.2
13.813.110.18.37.2
−0.1−0.10.00.20.0
13.713.010.18.57.3
Per share
₹1.67₹1.58₹1.22₹1.00₹0.87
₹1.67₹1.58₹1.22₹1.00₹0.87
Other comprehensive income — detail
−0.1−0.10.0——
—−0.1———
−0.0−0.0−0.0——
———−0.2−0.0
Per share — as-filed variants
₹1.67₹1.58₹1.22₹1.00₹0.87
₹1.67₹1.58₹1.22₹1.00₹0.87
Derived — gross profit (revenue − materials − purchases − Δ inventories)
57.855.042.635.035.6
24.3%26.7%28.2%24.2%25.3%
Adjusted (ex-exceptional items) — derived
19.018.113.511.310.1
13.813.110.18.37.2
₹1.67₹1.58₹1.22₹1.00₹0.87
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹19.22

Medico Remedies Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹160 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations140.4144.9150.9206.4237.5
Other Income3.92.12.75.96.4
Total Income144.4147.0153.6212.3244.0
Expenses
+ Cost of Materials Consumed100.1106.1111.4148.6167.1
+ Purchases of Stock-in-Trade6.01.82.14.45.0
+ Changes in Inventories-1.22.0-5.2-1.77.7
+ Employee Benefit Expense5.75.96.37.47.7
+ Finance Costs0.70.81.21.81.9
+ Depreciation & Amortisation2.72.93.03.13.0
+ Other Expenses20.316.221.330.632.6
Total Expenses134.3135.7140.1194.3225.0
EBITDA9.612.915.017.017.5
EBIT6.910.012.013.914.5
Profit
PBT before Exceptional Items10.111.313.518.119.0
Pretax Income10.111.313.518.119.0
+ Current Tax2.53.23.85.15.2
+ Deferred Tax0.4-0.1-0.4-0.1-0.1
Tax Expense2.93.03.44.95.2
Net Income7.28.310.113.113.8
+ Net Income — Continuing Ops7.28.310.113.113.8
+ Other Comprehensive Income0.00.20.0-0.1-0.1
Total Comprehensive Income7.38.510.113.013.7
Per Share
Basic EPS0.871.001.221.581.67
Diluted EPS0.871.001.221.581.67
Other Comprehensive Income — detail
+ Other Comprehensive Income——0.0-0.1-0.1
+ Items NOT to be Reclassified to P&L———-0.1—
+ Tax on Items NOT to be Reclassified——-0.0-0.0-0.0
+ Tax on Items NOT to be Reclassified — alt tag-0.0-0.2———
Per Share — as-filed variants
Basic EPS — Continuing Operations0.871.001.221.581.67
Diluted EPS — Continuing Operations0.871.001.221.581.67
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit35.635.042.655.057.8
Gross Margin %25.3324.1628.2326.6724.33
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)10.111.313.518.119.0
Net Income Adj (tax-effected)7.28.310.113.113.8
EPS Adj0.871.001.221.581.67
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.00—2.00
Filed Debt Equity0.000.000.000.250.01
Filed Dscr0.000.000.0011.160.10
Filed Iscr0.000.0020.3519.2211.00
Paid Up Equity Capital16.616.616.616.616.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.